(Q51026334)

English

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

scientific article published on 8 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. (English)

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Deepak B Khatry

object named as

Deepak B Khatry

11

0 references

William W Busse

6

object named as

William W Busse

1 reference

Europe PubMed Central

27 March 2018

Eugene R Bleecker

3

object named as

Eugene R Bleecker

1 reference

Europe PubMed Central

27 March 2018

5

object named as

Piotr Kuna

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

2

object named as

Sally E Wenzel

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

author name string

Mario Castro

1

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Emilio Pizzichini

4

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

David L Gossage

7

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Christine K Ward

8

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Yanping Wu

9

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Bing Wang

10

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

René van der Merwe

12

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Roland Kolbeck

13

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Nestor A Molfino

14

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Donald G Raible

15

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

publication date

8 October 2014

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

2

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

11

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

879-890

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Eosinophilic airway disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tissue and BAL based biomarkers in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic strategies to reduce asthma exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of a questionnaire to measure asthma control.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Full blood count parameters for the detection of asthma inflammatory phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of a standardized version of the Asthma Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

General considerations for lung function testing.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-interleukin-5 therapy in severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970201-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(14)70201-2

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/MED/25306557

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51026334&oldid=1753535623"